All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Tenpoint Therapeutics receives FDA approval for YUVEZZI (carbachol and brimonidine tartrate) combination eye drop treating presbyopia
Small molecule, ophthalmology, combination therapy, presbyopia, carbachol, brimonidine - Read more

THE GOOD
Business Development & Partnerships

Eli Lilly, Seamless Therapeutics partner on hearing loss gene editing platform worth over $1.12B
Licensing deal, rare disease, gene therapy, milestone payments - Read more

Nautilus Biotechnology, Weill Cornell Medicine-Qatar collaborate with Michael J. Fox Foundation on Parkinson's research, $1.6M grant
Research collaboration, neurological, drug discovery, biomarker development - Read more

iXCells Biotechnologies, Rosebud Biosciences partner to advance organoid-based models for rare diseases
Research collaboration, rare disease, drug discovery, organoid technology - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Boehringer Ingelheim starts Ph3 trial of apecotrep (BI 764198) targeting TRPC6 for primary focal segmental glomerulosclerosis
Small molecule, kidney disease, TRPC6 inhibitor, focal segmental glomerulosclerosis, proteinuria - Read more

THE GOOD
Fundraises

Eikon Therapeutics targets $274M IPO for four clinical-stage oncology candidates
Oncology, clinical-stage, small molecule, PARP inhibitor, immunotherapy, solid tumors - Read more

Antheia raises $24M Series C second close, biosynthetic drug ingredient manufacturing
Biosynthesis, manufacturing, platform technology, pharmaceutical supply chain - Read more

Cellares raises $257M Series D, cell therapy manufacturing platform expansion
Cell therapy, manufacturing, platform technology, CAR-T - Read more

Sensorion raises €60M ($71.56M) strategic funding, advancing genetic medicine pipeline for hearing loss
Gene therapy, hearing loss, clinical-stage, genetic medicine - Read more

Tenpoint Therapeutics raises $235M Series B, accelerating YUVEZZI presbyopia treatment commercialization
Ophthalmology, presbyopia, commercial-stage, vision treatments - Read more

CraniUS Therapeutics raises $20M Series B, advancing brain drug delivery platform
Neurological, platform technology, medical device, blood-brain barrier, implantable technology - Read more

Elysium Therapeutics raises $7.5M SAFE round, developing synthetic opioid overdose treatments
Overdose reversal, synthetic opioids, rescue treatment, biopharmaceutical - Read more

THE GOOD
Mergers & Acquisitions

Halozyme Therapeutics acquires Surf Bio for up to $400M to expand subcutaneous drug delivery portfolio
Drug delivery technology, strategic, major transaction, revenue impact - Read more

THE GOOD
Regulatory

HHS issues new DTC guidance to prevent pharma anti-kickback law violations in direct-to-consumer sales
Small molecule, obesity, regulatory, operational, strategic - Read more

American Academy of Pediatrics releases 2026 immunization schedule rebuking CDC's reduced childhood vaccine recommendations
Vaccine, infectious disease, strategic, competitive - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

CalciMedica halts Ph2 trial of Auxora calcium channel inhibitor for acute kidney injury over safety concerns
Small molecule, kidney disease, calcium channel inhibitor, acute kidney injury, safety concerns - Read more

THE BAD
Earnings & Finances

Teva expects 2026 revenue downturn after three consecutive years of growth under CEO Francis' transformation strategy
Long-acting injectable, neurological, financial, revenue impact - Read more

THE BAD
Regulatory

FDA halts Regenxbio gene therapy programs RGX-111 and RGX-121 after pediatric brain tumor detection
Gene therapy, rare disease, regulatory, operational - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here